| Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects (NCT02956499) | Basilea Pharmaceutica | 2016-05-24 |
| Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma (NCT02648633) | University of Virginia | 2016-05-24 |
| Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (NCT02609776) | Janssen Research & Development, LLC | 2016-05-24 |
| Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors (NCT02794571) | Genentech, Inc. | 2016-05-23 |
| Adrecizumab Phase 1 Trial (NCT02991508) | Radboud University Medical Center | 2016-05-23 |
| Topical Multiple Ascending Dose Study for PF-06423264 (NCT02778477) | Pfizer | 2016-05-23 |
| Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas (NCT02783625) | Memorial Sloan Kettering Cancer Center | 2016-05-23 |
| Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors (NCT02762981) | Corcept Therapeutics | 2016-05-23 |
| A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers (NCT02698553) | GlaxoSmithKline | 2016-05-23 |
| Study of Multiple Doses of Danicopan in Healthy Participants (NCT04889690) | Alexion Pharmaceuticals, Inc. | 2016-05-21 |
| HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma (NCT02569320) | Ohio State University Comprehensive Cancer Center | 2016-05-20 |
| R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (NCT02628405) | Academic and Community Cancer Research United | 2016-05-20 |
| Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer (NCT02751385) | Boehringer Ingelheim | 2016-05-20 |
| A Phase I Study to Investigate the ADME of KD101 (NCT02819934) | Seoul National University Hospital | 2016-05-20 |
| Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (NCT02639546) | Hoffmann-La Roche | 2016-05-20 |
| Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery (NCT02595918) | National Cancer Institute (NCI) | 2016-05-19 |
| A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005) (NCT02698189) | Merck Sharp & Dohme LLC | 2016-05-19 |
| Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine (NCT02645032) | International Vaccine Institute | 2016-05-19 |
| Vascularised Sentinel Skin Flaps to Detect Rejection in Pancreas Transplantation (NCT03183258) | University of Oxford | 2016-05-19 |
| Nicotinamide Riboside in Systolic Heart Failure (NCT03423342) | University of Washington | 2016-05-19 |
| Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis (NCT02763969) | Bristol-Myers Squibb | 2016-05-18 |
| Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies (NCT02711137) | Incyte Corporation | 2016-05-18 |
| Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab (NCT02649686) | Canadian Cancer Trials Group | 2016-05-17 |
| Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects (NCT02758171) | Boehringer Ingelheim | 2016-05-17 |
| Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome (NCT02553941) | Brian Jonas | 2016-05-17 |
| Magnesium Supplementation in People With XMEN Syndrome (NCT02496676) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-05-17 |
| Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis (NCT03241784) | The Methodist Hospital Research Institute | 2016-05-16 |
| A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations (NCT02790840) | Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2016-05-16 |
| A Phase 1 Study of ARN-6039 (NCT03237832) | Arrien Pharmaceuticals | 2016-05-16 |
| Mesenchymal Stem Cells (MSC) for Ovarian Cancer (NCT02530047) | M.D. Anderson Cancer Center | 2016-05-16 |
| Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease (NCT02370888) | University of Florida | 2016-05-16 |
| Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer (NCT02489214) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2016-05-16 |
| Evaluation of Clinical Efficacy of Autologous Adipose Tissue Derived ADSCSs in Treatment of Osteoarthritis (OA) (NCT05484856) | Dr. Himanshu Bansal Foundation | 2016-05-16 |
| A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (NCT02632448) | Esperas Pharma Inc. | 2016-05-16 |
| Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer. (NCT03497377) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-05-16 |
| GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients (NCT02575404) | Providence Health & Services | 2016-05-16 |
| A Study of Pevonedistat in Adult East Asian Participants (NCT02782468) | Millennium Pharmaceuticals, Inc. | 2016-05-16 |
| Treatment of Macrophage Activation Syndrome (MAS) With Anakinra (NCT02780583) | University of Alabama at Birmingham | 2016-05-15 |
| A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Metformin (NCT02760342) | Astellas Pharma Inc | 2016-05-15 |
| A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants. (NCT02839135) | GlaxoSmithKline | 2016-05-13 |
| Study to Evaluate the Clinical Efficacy of Streptococcus Dentisani CECT 7746 in Caries Risk Reduction (NCT03468842) | AB Biotics, SA | 2016-05-13 |
| A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1) (NCT02795325) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2016-05-13 |
| Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer (NCT02719691) | University of Colorado, Denver | 2016-05-13 |
| A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis (NCT02780388) | Amgen | 2016-05-12 |
| Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD (NCT02406651) | EVIVE Biotechnology | 2016-05-12 |
| Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma (NCT02613598) | University of Michigan Rogel Cancer Center | 2016-05-12 |
| A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis (NCT02603172) | GlaxoSmithKline | 2016-05-12 |
| Safety and Efficacy Study of Different DAV132 Dose Regimens in Healthy Volunteers (NCT02917200) | Da Volterra | 2016-05-11 |
| Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects (NCT03345043) | ModernaTX, Inc. | 2016-05-11 |
| Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor (NCT02496663) | National Cancer Institute (NCI) | 2016-05-11 |
| A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (NCT02733042) | Celgene | 2016-05-11 |
| Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV) (NCT02741557) | ViiV Healthcare | 2016-05-11 |
| A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) (NCT02759107) | Eli Lilly and Company | 2016-05-11 |
| Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies (NCT02668770) | M.D. Anderson Cancer Center | 2016-05-11 |
| Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (NCT02600949) | M.D. Anderson Cancer Center | 2016-05-11 |
| Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers (NCT05983328) | Sinew Pharma Inc. | 2016-05-10 |
| Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC (NCT03253133) | Institut du Cancer de Montpellier - Val d'Aurelle | 2016-05-10 |
| A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma (NCT02756247) | Memorial Sloan Kettering Cancer Center | 2016-05-09 |
| A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors (NCT02760797) | Hoffmann-La Roche | 2016-05-09 |
| Photosensitization Study in Androgenetic Alopecia (NCT02791243) | Polichem S.A. | 2016-05-09 |
| An Ascending Dose Study to Evaluate M281 Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) (NCT02828046) | Momenta Pharmaceuticals, Inc. | 2016-05-09 |
| Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study (NCT02748694) | Neurocrine Biosciences | 2016-05-09 |
| LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02652871) | M.D. Anderson Cancer Center | 2016-05-09 |
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer (NCT02769962) | National Cancer Institute (NCI) | 2016-05-09 |
| A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS) (NCT02714036) | MediciNova | 2016-05-06 |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors (NCT02611024) | PharmaMar | 2016-05-06 |
| A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential (NCT02706535) | GlaxoSmithKline | 2016-05-05 |
| A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors (NCT05086848) | Jiangsu HengRui Medicine Co., Ltd. | 2016-05-05 |
| Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants (NCT02769065) | Takeda | 2016-05-05 |
| An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies (NCT02712905) | Incyte Corporation | 2016-05-05 |
| Study of MEK162 for Children With Low-Grade Gliomas (NCT02285439) | Children's Hospital Los Angeles | 2016-05-04 |
| A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) (NCT02698176) | Merck Sharp & Dohme LLC | 2016-05-04 |
| Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT02649764) | M.D. Anderson Cancer Center | 2016-05-04 |
| Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema (NCT04191629) | Valeria Sanchez-Huerta | 2016-05-04 |
| Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT02676323) | St. Jude Children's Research Hospital | 2016-05-03 |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (NCT02650401) | Hoffmann-La Roche | 2016-05-03 |
| A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects (NCT02857868) | Novartis Pharmaceuticals | 2016-05-03 |
| Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial (NCT02561455) | Astellas Pharma Global Development, Inc. | 2016-05-03 |
| PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases (NCT02649985) | Brigham and Women's Hospital | 2016-05-02 |
| Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02642965) | Children's Oncology Group | 2016-05-02 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567. (NCT02760316) | AstraZeneca | 2016-05-02 |
| A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC) (NCT02564614) | Hoffmann-La Roche | 2016-05-02 |
| Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (NCT02720068) | Merck Sharp & Dohme LLC | 2016-05-02 |
| Phase I Study of TENPA in Advanced Solid Cancer (NCT02979392) | Yung-Jue Bang | 2016-05-02 |
| A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013) (NCT02750761) | Merck Sharp & Dohme LLC | 2016-05-02 |
| Safety and Exploratory Efficacy Study of Collagen Membrane With Mesenchymal Stem Cells in the Treatment of Skin Defects (NCT02672280) | South China Research Center for Stem Cell and Regenerative Medicine | 2016-05-01 |
| A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT02705469) | Zenith Epigenetics | 2016-05-01 |
| Bioequivalence Study of Ibuprofen 400 mg/10 mL Oral Suspension vs. MOMENTACT 400 mg Film-coated Tablet (NCT02902302) | Aziende Chimiche Riunite Angelini Francesco S.p.A | 2016-05-01 |
| Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Trigeminal Neuralgia. Safety Issues. (NCT02662972) | Norwegian University of Science and Technology | 2016-05-01 |
| Injectable Collagen Scaffold™ Combined With HUC-MSCs Transplantation for Patients With Decompensated Cirrhosis (NCT02786017) | Chinese Academy of Sciences | 2016-05-01 |
| The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens (NCT02413021) | Isfahan University of Medical Sciences | 2016-05-01 |
| Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors (NCT02644291) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-05-01 |
| TIBOHCA: Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After OHCA (NCT02836340) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2016-05-01 |
| Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies (NCT03366324) | Wuhan Sian Medical Technology Co., Ltd | 2016-05-01 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects (NCT02777008) | Concert Pharmaceuticals | 2016-05-01 |
| Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (NCT02665650) | Affimed GmbH | 2016-05-01 |
| Safety and Immunogenicity of a Vaccine Dendritic Cell-based Pulsed With Autologous Heat-inactivated in HIV-1 Infected Patients (NCT02767193) | Judit Pich Martínez | 2016-05-01 |
| A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates (NCT02762123) | Bristol-Myers Squibb | 2016-05-01 |
| A Study to Investigate the Pharmacokinetic Drug Interactions Between Dutasteride and Tadalafil in Healthy Male Subjects (NCT02839122) | Yuyu Pharma, Inc. | 2016-05-01 |
| A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure (NCT02772029) | The First Affiliated Hospital of Zhengzhou University | 2016-05-01 |